- Home
- VNRX vs NVNO Comparison
VNRX vs NVNO Comparison
Compare VNRX & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- NVNO
- Stock Information
- Founded
- VNRX N/A
- NVNO 1987
- Country
- VNRX United States
- NVNO United States
- Employees
- VNRX N/A
- NVNO N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NVNO Medical/Dental Instruments
- Sector
- VNRX Health Care
- NVNO Health Care
- Exchange
- VNRX Nasdaq
- NVNO Nasdaq
- Market Cap
- VNRX 52.4M
- NVNO 71.0M
- IPO Year
- VNRX N/A
- NVNO N/A
- Fundamental
- Price
- VNRX $0.72
- NVNO $3.95
- Analyst Decision
- VNRX Strong Buy
- NVNO
- Analyst Count
- VNRX 5
- NVNO 0
- Target Price
- VNRX $3.88
- NVNO N/A
- AVG Volume (30 Days)
- VNRX 321.6K
- NVNO 112.5K
- Earning Date
- VNRX 08-13-2025
- NVNO 07-30-2025
- Dividend Yield
- VNRX N/A
- NVNO N/A
- EPS Growth
- VNRX N/A
- NVNO N/A
- EPS
- VNRX N/A
- NVNO N/A
- Revenue
- VNRX $1,308,361.00
- NVNO N/A
- Revenue This Year
- VNRX $563.72
- NVNO N/A
- Revenue Next Year
- VNRX $160.43
- NVNO N/A
- P/E Ratio
- VNRX N/A
- NVNO N/A
- Revenue Growth
- VNRX 64.16
- NVNO N/A
- 52 Week Low
- VNRX $0.40
- NVNO $2.03
- 52 Week High
- VNRX $0.94
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- VNRX 53.14
- NVNO 49.70
- Support Level
- VNRX $0.62
- NVNO $3.89
- Resistance Level
- VNRX $0.76
- NVNO $4.06
- Average True Range (ATR)
- VNRX 0.10
- NVNO 0.22
- MACD
- VNRX -0.02
- NVNO -0.05
- Stochastic Oscillator
- VNRX 32.00
- NVNO 14.06
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.